Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1622-1633

  Ishihara, Tomoaki ^a   Tanaka, Ken Ichiro ^a   Tashiro, Saki ^a   Yoshida, Kosuke ^a   Mizushima, Tohru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Celecoxib; Rebamipide; Ulcer; Voltage dependent L type Ca2+ channel

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; CELECOXIB; INDOMETACIN; PROSTAGLANDIN E2; REBAMIPIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL PROTECTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH LESION; STOMACH MUCOSA; STOMACH PROTECTION; TREATMENT RESPONSE;

ALANINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; APOPTOSIS; CALCIUM CHANNELS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; GASTRIC MUCOSA; HUMANS; MICE; MICE, INBRED C57BL; PROTECTIVE AGENTS; PYRAZOLES; QUINOLONES; SULFONAMIDES;

EID: 77950080219     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.030     Document Type: Article

References (55)

1. Smalley W.E., Ray W.A., Daugherty J.R., Griffin M.R. Non-steroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995, 141:539-545.
2. Hawkey C.J. Non-steroidal anti-inflammatory drug gastropathy. Gastroenterology 2000, 119:521-535.
3. Barrier C.H., Hirschowitz B.I. Controversies in the detection and management of non-steroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989, 32:926-932.
4. Fries J.F., Miller S.R., Spitz P.W., Williams C.A., Hubert H.B., Bloch D.A. Toward an epidemiology of gastropathy associated with non-steroidal antiinflammatory drug use. Gastroenterology 1989, 96:647-655.
5. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
6. Kurata J.H., Abbey D.E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990, 12:260-266.
7. Vane J. Towards a better aspirin. Nature 1994, 367:215-216.
8. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998, 95:13313-13318.
9. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999, 290:551-560.
10. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000, 284:1247-1255.
11. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos V.R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528. 2 p following 8.
12. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442.
13. Juni P., Rutjes A.W., Dieppe P.A. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs?. Br Med J 2002, 324:1287-1288.
14. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., Gomollon F., Feu F., Gonzalez-Perez A., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
15. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996, 102:9-21.
16. Miller T.A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983, 245:G601-G623.
17. Tanaka K., Tomisato W., Hoshino T., Ishihara T., Namba T., Aburaya M., et al. Involvement of Intracellular Ca2+ Levels in non-steroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 2005, 280:31059-31067.
18. Tsutsumi S., Gotoh T., Tomisato W., Mima S., Hoshino T., Hwang H.J., et al. Endoplasmic reticulum stress response is involved in non-steroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 2004, 11:1009-1016.
19. Tomisato W., Tanaka K., Katsu T., Kakuta H., Sasaki K., Tsutsumi S., et al. Membrane permeabilization by non-steroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2004, 323:1032-1039.
20. Tomisato W., Tsutsumi S., Rokutan K., Tsuchiya T., Mizushima T. NSAIDs induce both necrosis and apoptosis in guinea pig gastric mucosal cells in primary culture. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1092-G1100.
21. Aburaya M., Tanaka K., Hoshino T., Tsutsumi S., Suzuki K., Makise M., et al. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. J Biol Chem 2006, 281:33422-33432.
22. Ishihara T., Hoshino T., Namba T., Tanaka K., Mizushima T. Involvement of up-regulation of puma in non-steroidal anti-inflammatory drug-induced apoptosis. Biochem Biophys Res Commun 2007, 356:711-717.
23. Tsutsumi S., Namba T., Tanaka K.I., Arai Y., Ishihara T., Aburaya M., et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 2006, 25:1018-1029.
24. Namba T., Hoshino T., Tanaka K., Tsutsumi S., Ishihara T., Mima S., et al. Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. Mol Pharmacol 2007, 71:860-870.
25. Tomisato W., Tsutsumi S., Hoshino T., Hwang H.J., Mio M., Tsuchiya T., et al. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem Pharmacol 2004, 67:575-585.
26. Suemasu S., Tanaka K., Namba T., Ishihara T., Katsu T., Fujimoto M., et al. A role for HSP70 in protecting against indomethacin-induced gastric lesions. J Biol Chem 2009, 284:19705-19715.
27. Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E., et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci 2005, 50(Suppl 1):S3-S11.
28. Haruma K., Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther 2003, 18(Suppl. 1):153-159.
29. Hiratsuka T., Futagami S., Shindo T., Hamamoto T., Ueki N., Suzuki K., et al. Rebamipide reduces indomethacin-induced gastric injury in mice via down-regulation of ICAM-1 expression. Dig Dis Sci 2005, 50(Suppl. 1):S84-S89.
30. Naito Y., Iinuma S., Yagi N., Boku Y., Imamoto E., Takagi T., et al. Prevention of indomethacin-induced gastric mucosal injury in helicobacter pylori-negative healthy volunteers: A comparison study rebamipide vs. famotidine. J Clin Biochem Nutr 2008, 43:34-40.
31. Kleine A., Kluge S., Peskar B.M. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993, 38:1441-1449.
32. Yoshikawa T., Naito Y., Tanigawa T., Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 1993, 43:363-366.
33. Murata H., Yabe Y., Tsuji S., Tsujii M., Fu H.Y., Asahi K., et al. Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells. Dig Dis Sci 2005, 50(Suppl 1):S70-S75.
34. Nagano Y., Matsui H., Muramatsu M., Shimokawa O., Shibahara T., Yanaka A., et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci 2005, 50(Suppl. 1):S76-S83.
35. Naito Y., Kajikawa H., Mizushima K., Shimozawa M., Kuroda M., Katada K., et al. Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression. Dig Dis Sci 2005, 50(Suppl. 1):S104-S112.
36. Ushijima H., Tanaka K., Takeda M., Katsu T., Mima S., Mizushima T. Geranylgeranylacetone protects membranes against non-steroidal anti-inflammatory drugs. Mol Pharmacol 2005, 68:1156-1161.
37. Tsutsumi S., Tomisato W., Takano T., Rokutan K., Tsuchiya T., Mizushima T. Gastric irritant-induced apoptosis in guinea pig gastric mucosal cells in primary culture. Biochim Biophys Acta 2002, 1589:168-180.
38. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
39. Laudanno O.M., Cesolari J.A., Esnarriaga J., Rista L., Piombo G., Maglione C., et al. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 2001, 46:779-784.
40. Makin G.W., Corfe B.M., Griffiths G.J., Thistlethwaite A., Hickman J.A., Dive C. Damage-induced Bax n-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. Embo J 2001, 20:6306-6315.
41. Johnson A.J., Hsu A.L., Lin H.P., Song X., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002, 366:831-837.
42. Wang J.L., Lin K.L., Chen J.S., Lu Y.C., Jiann B.P., Chang H.T., et al. Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts. Biochem Pharmacol 2004, 67:1123-1130.
43. Moore R.A., Derry S., Phillips C.J., McQuay H.J. Non-steroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006, 7:79.
44. Lam S.K., Hasan M., Sircus W., Wong J., Ong G.B., Prescott R.J. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980, 21:324-328.
45. Cheng F.C., Lam S.K., Ong G.B. Maximum acid output to graded doses of pentagastrin and its relation to parietal cell mass in Chinese patients with duodenal ulcer. Gut 1977, 18:827-832.
46. Sun W.H., Tsuji S., Tsujii M., Gunawan E.S., Kawai N., Kimura A., et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther 2000, 295:447-452.
47. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000, 1:11-21.
48. Tanaka T., Nangaku M., Miyata T., Inagi R., Ohse T., Ingelfinger J.R., et al. Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 2004, 15:2320-2333.
49. Zawadzki A., Liu Q., Wang Y., Melander A., Jeppsson B., Thorlacius H. Verapamil inhibits L-type calcium channel mediated apoptosis in human colon cancer cells. Dis Colon Rectum 2008, 51:1696-1702.
50. Kobayashi T., Zinchuk V.S., Garcia del Saz E., Jiang F., Yamasaki Y., Kataoka S., et al. Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. Histol Histopathol 2000, 15:1067-1076.
51. Murakami K., Okajima K., Harada N., Isobe H., Okabe H. Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci 1998, 43:139S-142S.
52. 2+ on rapid and transient contents of superoxide generation in differentiated THP-1 cells. Biochem Biophys Res Commun 2006, 344:571-580.
53. Shen Y.C., Chen C.F., Wang S.Y., Sung Y.J. Impediment to calcium influx and reactive oxygen production accounts for the inhibition of neutrophil Mac-1 Up-regulation and adhesion by tetrandrine. Mol Pharmacol 1999, 55:186-193.
54. Zanner R., Hapfelmeier G., Gratzl M., Prinz C. Intracellular signal transduction during gastrin-induced histamine secretion in rat gastric ECL cells. Am J Physiol Cell Physiol 2002, 282:C374-C382.
55. Triggle D.J. Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol 2007, 74:1-9.